Clinical efficacy of gemcitabine combined with lobaplatin interventional embolization therapy for treating HBV infected hepatocellular carcinoma and its influence on levels of serum tumor biomarkers
10.3969/j.issn.1673-4130.2018.01.010
- VernacularTitle:吉西他滨联合洛铂介入栓塞治疗HBV感染性肝癌的疗效及其对血清肿瘤标志物水平的影响
- Author:
Xiaoli ZHOU
1
;
Guoming SU
;
Bo JIANG
;
Zengtao XU
;
Xiaolin LIAO
;
Jie ZHANG
Author Information
1. 四川护理职业学院药学与检验系
- Keywords:
gemcitabine;
lobaplatin;
interventional embolization;
hepatitis B virus;
hepatocellular carcinoma
- From:
International Journal of Laboratory Medicine
2018;39(1):38-41,45
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the short term and long term clinical efficacy of gemcitabine combined with lobaplatin interventional embolization therapy for the treatment of hepatitis B virus (HBV) infected hepa-tocellular carcinoma (HCC) and its influence on the levels of serum tumor biomarkers .Methods A total of 62 cases of HBV infected HCC in the first affiliated hospital of Chengdu Medical University from June 2012 to January 2015 were selected as the research subjects and randomly divided into the intravenous drip of gemcit-abine plus lobaplatin treatment group (control group) and gemcitabine plus lobaplatin via hepatic artery hy-perthermal perfusion chemotherapy embolism group (embolization group) ,31 cases in each group .The short term and long term clinical efficacy and the changes of serum tumor biomarkers levels were compared between the two groups .Results The total effective rate in the control group was 48 .39％ (15/31) ,which was signifi-cantly lower than 83 .87％ (26/31) in the embolization group ,the difference was statistically significant (P<0 .05);moreover ,the disease control rate in the embolization group was 93 .55％ (29/31) ,which also was sig-nificantly higher than 74 .19％ (23/31) in the control group ,the difference was statistically significant ( P<0 .05);however ,there were no statistically significant difference in the incidence rate of adverse reactions ,av-erage survival time ,1-year and 2-year survival rates between the two groups (P>0 .05);after treatment ,the serum tumor biomarkers CEA ,NSE ,CYFRA21-1 ,CA125 and CA19-9 levels in the two groups were signifi-cantly decreased compared with those before treatment (P<0 .05);the levels of serum tumor markers after treatment had statistical difference between the embolization group and control group (P<0 .05) .Conclusion Gemcitabine combined with lobaplatin interventional embolization therapy can significantly improve the clini-cal efficacy of HBV infected HCC ,and can significantly improve the level of serum tumor biomarkers .
